Upstream Processing

Amgen to build biologics drug substance manufacturing facility in North Carolina

04-Aug-2021 By Rachel Arthur

Amgen will build a new multi-product drug substance manufacturing facility in Holly Springs, North Carolina.

Spotlight on single-use systems: 3 trends driving demand

03-Aug-2021 By Staff reporter

Adoption of single-use technologies has grown exponentially over the last decade: but what will drive the tech forward in the coming years?

Sartorius downplays threat of Chinese regulatory changes to single-use tech

02-Aug-2021 By Nick Taylor

Sartorius has expressed confidence that demand for single-use technologies will be unaffected by changes to the regulation of biologics in China.

Cytiva and Pall to spend $1.5bn on manufacturing capacity expansion, new hires

27-Jul-2021 By Jane Byrne

Cytiva and Pall Corporation, both subsidiaries of Danaher Corporation, have announced they are to invest US$1.5bn to expand manufacturing capacity across 13 sites globally

Biotech Absci sees shares soar in IPO debut

27-Jul-2021 By Jane Byrne

Absci Corp, a Vancouver, Washington headquartered synthetic biology company developing technologies to accelerate drug discovery, has gone public.

PerkinElmer to acquire antibody and reagent company BioLegend for $5bn

26-Jul-2021 By Rachel Arthur

PerkinElmer will make the largest transaction in its history with the acquisition of California’s BioLegend for $5.25bn.

Generate looks to in-house stem cell manufacturing

22-Jul-2021 By Jane Byrne

Generate Life Sciences is establishing a GMP facility in La Jolla, California that it says will enable end-to-end manufacturing of newborn stem cell biologics, bolstering supply and safeguarding clinical research.

Kineta and Samsung Biologics sign agreement for development and manufacture of anti-VISTA antibody immunotherapy

20-Jul-2021 By Rachel Arthur

Kineta says the partnership with Samsung Biologics will help it advance its novel anti-VISTA antibody as it aims to start clinical trials next year.

Pall inks $7m deal with Exothera for suspension based production of viral vectors

19-Jul-2021 By Jane Byrne

Filtration, separation and purification specialist, Pall, has announced a new contract valued at over US$7M with full-service CDMO, Exothera.

GentiBio and Forge Biologics in viral vector contract development and GMP manufacturing partnership

19-Jul-2021 By Jane Byrne

Boston headquartered biotherapeutics company, GentiBio, Inc, and CGT focused CDMO, Forge Biologics, have set up a development and manufacturing partnership.

Univercells Technologies in tie-up with Chinese player on viral vectors for CGT and vaccine sectors

12-Jul-2021 By Jane Byrne

Belgium’s Univercells Technologies and China’s VectorBuilder have entered a strategic global partnership for custom viral vector production.

Fujifilm continues to expand its biologics CDMO business, ploughing further $850m into US and UK sites

08-Jul-2021 By Jane Byrne

Fujifilm Corporation has made an additional US$850m investment to enable the expansion of its BIO-CMDO sites in the UK, at Billingham, and in the US.

AGC Biologics to acquire cell and gene therapy manufacturing facility in Longmont, Colorado

05-Jul-2021 By Rachel Arthur

CDMO AGC Biologics will purchase a cell and gene therapy commercial manufacturing facility in Longmont, Colorado, from Novartis Gene Therapies.

Sartorius acquires majority stake in CellGenix

05-Jul-2021 By Rachel Arthur

Sartorius is strengthening its product portfolio for cell and gene therapies with the acquisition of a majority stake in German reagent manufacturer CellGenix.

Cobra flags successful production of plasmids for epilepsy targeted gene therapy

30-Jun-2021 By Jane Byrne

Cobra Biologics, the gene therapy division of the Charles River owned Cognate BioServices, and Sweden's CombiGene recently announced the successful production and quality assurance of the plasmids to be used in the GMP production of the gene therapy,...